Monoclonal antibodies against HER1 [31] and HER2 [31], [32], [33], [34], [35] as well as EGF, the natural ligand of HER1 [36], [37], [38], have been successfully used as targeting moieties for the design of anti-tumor contrast agents based on QDs. Here, ERBB2 is linked to neoplasm.